Literature DB >> 22491269

Biologics inch toward cholesterol-lowering market.

Ken Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22491269     DOI： 10.1038/nbt0412-302

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Safety signal dampens reception for mipomersen antisense.

Authors:  Jim Kling
Journal:  Nat Biotechnol       Date:  2010-04       Impact factor: 54.908

2.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245
  2 in total
  4 in total

1.  Proof of concept for next-generation nanoparticle drugs in humans.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2012-06-07       Impact factor: 54.908

2.  New class PCSK9 blockers stride into cholesterol market.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2015-08       Impact factor: 54.908

3.  Antisense battles small molecule for slice of rare lipid disorder market.

Authors:  Gunjan Sinha
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

Review 4.  PCSK9 antibodies for the treatment of hypercholesterolemia.

Authors:  Ioanna Gouni-Berthold; Heiner K Berthold
Journal:  Nutrients       Date:  2014-12-01       Impact factor: 5.717
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.